Ned 19是一种选择性的 NAADP 拮抗剂,具有膜透性,能够以非竞争性机制抑制 NAADP 介导的 Ca2+ 信号通路,IC50 为 65 nM。Ned 19 强烈抑制肿瘤生长、血管生成和肺转移,在抗癌领域具有广泛应用前景。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} {[ size_append(item.pr_size_append, item.pr_am, item.pr_size) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | Ca2+ channel-like protein ↓ ↑ | Calcium Channel ↓ ↑ | Cav 2.2 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CDC25B-IN-2 | ✔ | Akt | 99%+ | ||||||||||||||||
| Clevidipine | ✔ | 97% | |||||||||||||||||
| Verapamil HCl | ✔ | 99% | |||||||||||||||||
| Amlodipine | ✔ | 99% | |||||||||||||||||
| Amlodipine maleate | ✔ | 98% | |||||||||||||||||
| (+)-cis-Diltiazem HCl | ✔ | 99% | |||||||||||||||||
| Zegocractin |
++
Orai1/STIM1-mediated Ca2+ currents, IC50: 120 nM |
99%+ | |||||||||||||||||
| Tanshinone IIA sulfonate sodium | ✔ | 98% | |||||||||||||||||
| Ulixacaltamide |
++
hCaV3.1, IC50: 50 nM hCaV3.2, IC50: 110 nM |
99%+ | |||||||||||||||||
| Dronedarone HCl | ✔ | 95% | |||||||||||||||||
| Nitrendipine |
+
Calcium channel, IC50: 95 nM |
98% | |||||||||||||||||
| Efonidipine HCl monoethanolate | ✔ | 98% | |||||||||||||||||
| Cinnarizine | ✔ | 98% | |||||||||||||||||
| SEA0400 |
++
NCX, IC50: 33 nM |
p38 MAPK,ERK,ROS | 99%+ | ||||||||||||||||
| Fasudil HCl | ✔ | Rho,PKA | 98% | ||||||||||||||||
| ML-9 | ✔ | Akt,MLCK | 99%+ | ||||||||||||||||
| Flunarizine 2HCl |
+
Calcium channel, Ki: 68 nM |
95% | |||||||||||||||||
| Lomerizine 2HCl | ✔ | 98% | |||||||||||||||||
| Efonidipine | ✔ | 98% | |||||||||||||||||
| Levamlodipine | ✔ | 98% | |||||||||||||||||
| Nisoldipine |
++
L-type Cav1.2, IC50: 10 nM |
97% | |||||||||||||||||
| Isradipine | ✔ | 98% | |||||||||||||||||
| Lacidipine | ✔ | 98% | |||||||||||||||||
| Lercanidipine | ✔ | 99% | |||||||||||||||||
| Loureirin B | ✔ | Potassium Channel | 99%+ | ||||||||||||||||
| Tetracaine HCl | ✔ | 98% | |||||||||||||||||
| Manidipine |
+++
Calcium channel, IC50: 2.6 nM |
99% | |||||||||||||||||
| Manidipine Dihydrochlorid |
+++
Calcium channel, IC50: 2.6 nM |
98% | |||||||||||||||||
| Nicardipine | ✔ | 99% | |||||||||||||||||
| Wilforgine | ✔ | 98+% | |||||||||||||||||
| Econazole | ✔ | 99%+ | |||||||||||||||||
| Ginsenoside Rd | ✔ | NF-κB | 98% | ||||||||||||||||
| Fendiline HCl | ✔ | 98+% | |||||||||||||||||
| Mesaconitine | ✔ | 98% | |||||||||||||||||
| Tetrandrine | ✔ | 95% | |||||||||||||||||
| Nifedipine | ✔ | 98% | |||||||||||||||||
| Nilvadipine |
++++
Calcium channel, IC50: 0.03 nM |
95% | |||||||||||||||||
| Barnidipine |
++++
[3H]nitrendipine, Ki: 0.21 nM |
95+% | |||||||||||||||||
| Azelnidipine | ✔ | 97% | |||||||||||||||||
| Levetiracetam | ✔ | 98% | |||||||||||||||||
| Nimodipine | ✔ | 95% | |||||||||||||||||
| Benidipine HCl | ✔ | 98% | |||||||||||||||||
| Pinaverium bromide | ✔ | 98% | |||||||||||||||||
| Pranidipine | ✔ | 99% | |||||||||||||||||
| NP118809 |
+
N-type Ca2+ channel, IC50: 0.11 μM L-type calcium channel, IC50: 12.2 μM |
95% | |||||||||||||||||
| Amlodipine Besylate |
+++
Calcium channel, IC50: 1.9 nM |
97% | |||||||||||||||||
| Cilnidipine | ✔ | 99% | |||||||||||||||||
| Cinepazide Maleate | ✔ | 99% (HPLC) | |||||||||||||||||
| Terfenadine | ✔ | 98% | |||||||||||||||||
| YM-58483 | ✔ | 99%+ | |||||||||||||||||
| Amiloride HCl | ✔ | 98% | |||||||||||||||||
| Ranolazine | ✔ | 98% | |||||||||||||||||
| Praeruptorin A | ✔ | p38 MAPK,Akt | 98% | ||||||||||||||||
| Ranolazine 2HCl | ✔ | 98% | |||||||||||||||||
| Felodipine |
++++
L-type calcium channel, IC50: 0.15 nM |
98% | |||||||||||||||||
| PD173212 |
+++
N-type Ca2+ channel, IC50: 36 nM |
98% | |||||||||||||||||
| Levamlodipine besylate | ✔ | 97% | |||||||||||||||||
| Carboxyamidotriazole Orotate | ✔ | 98% | |||||||||||||||||
| IGS-1.76 | ✔ | 98+% | |||||||||||||||||
| WH-4-023 |
++++
Cav 2.2, IC50: 0.001 μM |
++++
Cav 2.2, IC50: 0.001 μM |
99%+ | ||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 描述 | Ned 19 is a selective, membrane-permeable, non-competitive NAADP antagonist that inhibits NAADP-mediated Ca2+ signalling with an IC50 value of 65 nM[1] .Ned 19 strongly inhibits tumour growth, angiogenesis and lung metastasis in mice.Ned 19 acts in the concentration range of 25-100 μM for 24-72 hours, decreases the percentage of B16 cells in S phase, increases the percentage in G0/G1 phase, induces apoptosis in a concentration- and time-dependent manner, and reduces cell proliferation.Ned 19 decreases N-adhesin expression and increases E-adhesin expression and affects cell migration behaviour[2]. |
| Concentration | Treated Time | Description | References | |
| Sea urchin egg homogenate | 10 µM | 3-5 min | Inhibition of NAADP-mediated Ca2+ release | J Biol Chem. 2009 Dec 11;284(50):34930-4 |
| Memory CD4+T cells | 50-300 µM | 1 hour | Investigated the effect of Ned-19 on TCR-mediated calcium flux, showing stimulation at 50-200 µM and inhibition at 250-300 µM | Molecules. 2024 Feb 19;29(4):907 |
| Sea urchin egg homogenate | 65 nM | 3-5 min | Inhibition of NAADP-mediated Ca2+ release | J Biol Chem. 2009 Dec 11;284(50):34930-4 |
| Human umbilical vein endothelial cells (HUVECs) | 25 µM (cis- and trans-NED 19) | 10 minutes | To evaluate the inhibitory effect of NED 19 on histamine-induced [Ca2+]i rise. Results showed that both cis- and trans-NED 19 significantly inhibited histamine-induced [Ca2+]i rise. | Cells. 2019 Sep 25;8(10):1144 |
| Rat aortic smooth muscle cells | 5 µM (cis-NED 19), 25 µM (cis-NED 19), 50 µM (trans-NED 19) | 10 minutes | To evaluate the inhibitory effect of NED 19 on norepinephrine (NE)-induced [Ca2+]i rise. Results showed that cis- and trans-NED 19 inhibited NE-induced [Ca2+]i rise by approximately 50-60%. | Cells. 2019 Sep 25;8(10):1144 |
| Primary murine CD4+ T cells | various concentrations | 16 hours | To assess the role of NAADP signaling in T cell metabolic reprogramming, results showed that trans-Ned 19 inhibited TCR-induced metabolic upregulation. | Cells. 2021 Nov 5;10(11):3039 |
| Human umbilical vein endothelial cells (HUVECs) | 100 µM | 30 min | Ned-19 abolished VEGF-induced Ca2+ release, impairing phosphorylation of ERK1/2, Akt, eNOS, JNK, cell proliferation, cell migration, and capillary-like tube formation. | Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):E4706-15 |
| Primary murine CD4+ T cells | various concentrations | 30 minutes | To assess the role of NAADP signaling in TCR-induced Ca2+ signaling, results showed that trans-Ned 19 inhibited Ca2+ signaling in a concentration-dependent manner. | Cells. 2021 Nov 5;10(11):3039 |
| Metastatic colorectal cancer cells | 100 µM | 30 minutes | Blocked NAADP-induced Ca2+ release, reduced FBS-induced Ca2+ signals and cell proliferation | Cancers (Basel). 2019 Apr 15;11(4):542 |
| B16 melanoma cells | 25, 50, 100 µM | 30 minutes | To evaluate the role of NAADP-dependent acidic Ca2+ stores in VEGF-induced Ca2+ signaling, results showed that Ned-19 concentration-dependently inhibits VEGF-induced Ca2+ release | Sci Rep. 2016 Jan 6;6:18925 |
| Administration | Dosage | Frequency | Description | References | ||
| Mice | Ischemia-reperfusion injury model | Reperfusion solution | 10 μmol/L | 60 minutes of reperfusion | To evaluate the effect of Ned-19 on infarct size and left ventricular functional recovery during reperfusion. Results showed that Ned-19 treatment significantly reduced infarct size and improved left ventricular functional recovery in KI mice. | Circulation. 2021 Feb 2;143(5):449-465 |
| Mice | Pancreatic beta cells | Bathing solution | 100 μM | 30 min pre-incubation | Ned-19 reduced the amplitude of glucose-induced Ca2+ signals in a concentration-dependent manner with an IC50 of 3 μM, demonstrating a key causal link between NAADP signaling and glucose-induced Ca2+ increases. | Nat Chem Biol. 2009 Apr;5(4):220-6 |
| Mice | IL-17A fate mapping mouse model | Intraperitoneal injection | 20 mg/kg | Once daily for one week | To assess the effect of NAADP inhibition on the conversion of Th17 cells into regulatory T cells, results showed that trans-Ned 19 promoted the conversion of Th17 cells into regulatory T cells. | Cells. 2021 Nov 5;10(11):3039 |
| C57BL/6 mice | B16 melanoma transplant model | Intraperitoneal injection | 5 mg/kg | Every second day for 4 weeks | To evaluate the effect of Ned-19 on tumor growth, vascularization, and metastasis, results showed that Ned-19 significantly inhibited tumor growth, vascularization, and lung metastases | Sci Rep. 2016 Jan 6;6:18925 |
| C57BL/6 mice | Matrigel plug assay | Subcutaneous injection | 50, 100, 150 μmol/L | Single injection, duration of 5 days | Ned-19 inhibits VEGF-induced vessel formation in matrigel plugs in mice, with significantly reduced hemoglobin content. | Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):E4706-15 |
| Animal study | Administered at a dose of 5 mg/kg/every other day, intraperitoneally for 4 weeks, Ned 19 significantly inhibited tumour growth in a mouse model[2] . |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
1.94mL 0.39mL 0.19mL |
9.72mL 1.94mL 0.97mL |
19.43mL 3.89mL 1.94mL |
|
| CAS号 | 874374-25-1 |
| 分子式 | C30H31FN4O3 |
| 分子量 | 514.59 |
| SMILES Code | O=C(C1CC2=C(C(C3=CC=C(OC)C(CN4CCN(C5=CC=CC=C5F)CC4)=C3)N1)NC6=C2C=CC=C6)O |
| MDL No. | MFCD02057367 |
| 别名 | |
| 运输 | 蓝冰 |
| InChI Key | FUHCEERDBRGPQZ-UHFFFAOYSA-N |
| Pubchem ID | 3978027 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, 2-8°C |
| 溶解方案 |
DMSO: 120 mg/mL(233.2 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
沪公网安备 31011702889066号
沪ICP备2024050318号-1